ACRV Should I Buy

ACRV is not a good buy right now for a Beginner, long-term investor who doesn’t want to wait for optimal entry points. The stock is a low-priced, pre-revenue biotech with worsening losses (2025/Q3) and no fresh news catalysts this week, while the technical setup is neutral-to-weak and Intellectia has no buy signals today. I would hold/avoid new money at current levels and only reconsider after a clear catalyst (trial/IND progress) or a decisive technical breakout above near-term resistance.

Pre-market: $1.98 (-1.52%). Trend/momentum is mixed-to-bearish: MACD histogram is below 0 (-0.00263) and still contracting negatively (weak momentum), RSI(6)=46.6 (neutral), and moving averages are converging (no strong trend confirmation). Key levels: Pivot 1.901 (price slightly above), support S1 1.664 then S2 1.518; resistance R1 2.138 then R2 2.284. With price sitting just above the pivot and below resistance, the chart does not currently signal a strong long-term entry. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.